Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's (NOVOb.CO) , opens new tab Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the ...
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are ...
FAT jabs could be the cancer hope of the future after early studies found they reduce the risk of tumours. The world’s top ...
Medicare just revised its guidelines to include coverage of Wegovy for patients with cardiovascular complications.
The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs analysts said in a research note.
Lilly’s Trulicity and Novo Nordisk’s Ozempic have rocketed into Medicare’s top-10 spending list. That sets them up to be ...
Les actions européennes progressent grâce aux valeurs technologiques à l'approche de la décision de la BCE 06/06 RE Novo Nordisk fait face à la concurrence en Chine pour l'ingrédient clé de ...